Provenge Drug Maker Dendreon Said to Be Seeking Takeover Offers

Dendreon Corp. (DNDN), the drugmaker whose market value has shrunk by more than half since August, is seeking a buyer after sales of its prostate-cancer treatment failed to meet expectations, said people familiar with the matter.

Dendreon, the maker of Provenge, is working with JPMorgan Chase & Co. (JPM) to find suitors, said one of the people, who asked not to be named as the process is private. The company, whose market value once topped $7 billion, has generated about $2 billion in losses over the past decade. That market capitalization now hovers at about $400 million.

Dendreon said in early August that sales of Provenge, its sole marketed product, wouldn’t increase this year as forecast. When the treatment won approval in 2010, analysts projected the drug could generate $4.3 billion in sales by 2020. Today the estimate for that period has shrunk to $476.5 million.

Dendreon, led by Chairman and Chief Executive Officer John Johnson, has burned through money for at least six straight quarters. Cash and short-term investments had dropped to $207.4 million as of June from $538.6 million at the end of 2011.

Andy Brimmer, a spokesman for Seattle-based Dendreon with Joele Frank Wilkinson Brimmer Katcher, yesterday declined to comment on any sale process. A JPMorgan spokeswoman also declined to comment.

Photographer: Kevin P. Casey/Bloomberg

Dendreon Corp. said in early August that sales of Provenge, its sole marketed product, wouldn’t increase this year as forecast. Close

Dendreon Corp. said in early August that sales of Provenge, its sole marketed product,... Read More

Close
Open
Photographer: Kevin P. Casey/Bloomberg

Dendreon Corp. said in early August that sales of Provenge, its sole marketed product, wouldn’t increase this year as forecast.

Dendreon advanced 5 percent yesterday to close at $2.53 in New York.

To contact the reporters on this story: David Welch in New York at dwelch12@bloomberg.net; Beth Jinks in New York at bjinks1@bloomberg.net; Meg Tirrell in New York at mtirrell@bloomberg.net

To contact the editors responsible for this story: Jeffrey McCracken at jmccracken3@bloomberg.net; Reg Gale at rgale5@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.